Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Non-Current Deffered Revenue (2022 - 2024)

Praxis Precision Medicines (PRAX) has 3 years of Non-Current Deffered Revenue data on record, last reported at $293000.0 in Q3 2024.

  • For Q3 2024, Non-Current Deffered Revenue fell 80.67% year-over-year to $293000.0; the TTM value through Sep 2024 reached $293000.0, down 80.67%, while the annual FY2023 figure was $1.2 million, 46.79% down from the prior year.
  • Non-Current Deffered Revenue reached $293000.0 in Q3 2024 per PRAX's latest filing, down from $588000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $2.2 million in Q4 2022 and bottomed at $293000.0 in Q3 2024.
  • Average Non-Current Deffered Revenue over 3 years is $1.2 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Non-Current Deffered Revenue: tumbled 46.79% in 2023, then tumbled 80.67% in 2024.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $2.2 million in 2022, then plummeted by 46.79% to $1.2 million in 2023, then crashed by 74.76% to $293000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $293000.0 in Q3 2024, $588000.0 in Q2 2024, and $866000.0 in Q1 2024.